Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant lactococcus lactis expressing ovalbumin
- Development stage
- Preclinical
- Lead developer
- Xinjiang University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral, Intradermal
01
Overview
Recombinant *Lactococcus lactis* expressing ovalbumin is a genetically engineered live biologic platform used primarily as a research tool in immunology and oncology. The probiotic bacterium *Lactococcus lactis* (often strain MG1363) is modified to express or secrete chicken ovalbumin (OVA), a model antigen. In therapeutic research, it is utilized to induce mucosal immune tolerance for treating allergic or autoimmune diseases or as an adjuvant-antigen delivery vehicle for dendritic cell-based cancer vaccines. The bacterium interacts with the immune system by promoting dendritic cell maturation through the Toll-like receptor 2 (TLR2) pathway and enhancing antigen cross-presentation via the phagosome-to-cytosol pathway. This process is dependent on reactive oxygen species (ROS) production and proteasomal degradation, leading to the activation of antigen-specific CD8+ cytotoxic T lymphocytes and Th1 responses.
- Other names
- OVA recombinant L.LLactococcus lactis expressing OVArecombinant Lactococcus lactis secreting ovalbumin
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on recombinant lactococcus lactis expressing ovalbumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant lactococcus lactis expressing ovalbumin.